Folate Receptor Targeted Alpha-Therapy Using Terbium-149

Folate Receptor Targeted Alpha-Therapy Using Terbium-149

Terbium-149 is among the most interesting therapeutic nuclides for medical applications. It decays by emission of short-range α-particles (Eα = 3.967 MeV) with a half-life of 4.12 h. The goal of this study was to investigate the anticancer efficacy of a 149Tb-labeled DOTA-folate conjugate (cm09) us...

Full description

Bibliographic Details
Main Authors: Cristina Müller, Josefine Reber, Stephanie Haller, Holger Dorrer, Ulli Köster, Karl Johnston, Konstantin Zhernosekov, Andreas Türler, Roger Schibli
Format: Article
Language:English
Published: MDPI AG 2014-03-01
Series:Pharmaceuticals
Subjects:
terbium-149
alpha-therapy
folate receptor
DOTA-folate
KB tumors
149Tb-cm09
albumin binder, radionuclide therapy
Online Access:http://www.mdpi.com/1424-8247/7/3/353

Similar Items

Similar Items